Bicyclic And Tricyclic Compounds As KAT II Inhibitors
申请人:Claffey Michelle M.
公开号:US20100324043A1
公开(公告)日:2010-12-23
Compounds of Formula X:
wherein A, X, Y, Z, R
5
, R
6a
, and R
6b
are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.
BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS
申请人:Pfizer Inc.
公开号:EP2443092B1
公开(公告)日:2015-04-08
US8183238B2
申请人:——
公开号:US8183238B2
公开(公告)日:2012-05-22
A General Strategy for the Synthesis of Cyclic <i>N</i>-Aryl Hydroxamic Acids via Partial Nitro Group Reduction
作者:Laura A. McAllister、Bruce M. Bechle、Amy B. Dounay、Edelweiss Evrard、Xinmin Gan、Somraj Ghosh、Ji-Young Kim、Vinod D. Parikh、Jamison B. Tuttle、Patrick R. Verhoest
DOI:10.1021/jo200530j
日期:2011.5.6
We describe a generalized approach to stereocontrolled synthesis of substituted cyclichydroxamicacids (3-amino-1-hydroxy-3,4-dihydroquinolinones) by selective reduction of substituted 2-nitrophenylalanine substrates. Compounds in this series have antibacterial properties and have also recently been reported as KAT II inhibitors. The key nitrophenyl alanine intermediates are prepared enantioselectively